The GLP-1 pen is working. Hunger is quiet. The easy calories that used to disappear between meetings no longer call as loud. This is the feature. It is also the setup for GLP-1 muscle loss, the half of the result that the before-and-after photo never shows.

When total intake collapses without a plan, protein collapses with it. The body in a deep deficit will spend lean tissue. Some of that may be acceptable on the way to clearing visceral fat and dropping under a personal fat threshold. Some of it is the slow erasure of the organ that will determine how you age: muscle. I argued that the shot does not train for you. This is the operational sequel. If the protocol has no protein number, it is not a longevity protocol.

Why GLP-1 muscle loss starts with protein

GLP-1 receptor agonists slow gastric emptying and cut appetite. People skip meals. When they eat, they often reach for what is easy, not what is dense in essential amino acids. Surveys and clinic anecdotes rhyme: patients “forget” to eat, then celebrate the scale. Celebration is not composition.

Weight-loss physiology is old news. In calorie deficit, nitrogen balance is under threat unless protein is high and the stimulus to keep muscle is present. GLP-1s do not repeal that. They make the default deficit steeper and quieter.

How much of the loss is lean tissue is genuinely contested, and the honest version of the argument says so. The 2024 review by Neeland, Linge and Birkenfeld found trials reporting lean mass reductions of 40 to 60 percent of total weight lost, and other trials reporting 15 percent or less.^[1] Part of that spread is measurement: DEXA “lean mass” includes water and organ tissue, not only muscle. Part of it is that nobody standardized the eating or the training underneath the drug. The body-composition data from STEP 1 sits inside that range: of a mean 13.6 kg reduction, 8.3 kg was fat mass and 5.3 kg, roughly 38 percent, was lean mass.^[2] The reviews disagree about the number. None of them report zero.

Grams, not vibes

I will not pretend one number fits every body. I will pretend that having no number is a decision, and a bad one.

The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society puts the target during active weight reduction at 1.2 to 1.6 g of protein per kg per day, against a sedentary RDA of 0.8 g/kg/day, and advises against sustained intakes above 2 g/kg/day.^[2] That is the number to write down.

The same advisory is honest about what remains unresolved: whether that kilogram should be actual body weight, adjusted or ideal body weight, or fat-free mass. For a person with obesity the three answers are not close together, which is why the advisory also offers an absolute target of 80 to 120 g per day, or 16 to 24 percent of energy on a 2000 kcal diet, as the version patients can actually hit. Kidney disease, pregnancy and some liver conditions change the calculation, and that is a conversation with a clinician, not with a blog.

If nausea limits volume, the answer is higher protein density per bite, not surrender: dairy, eggs, fish, lean meat, whey if tolerated, texture hacks, smaller and more frequent feeds if large meals bounce. Track adherence the boring way. If the drug removes the cue of hunger, you need a schedule. Hunger was a terrible dietitian. Absence of hunger is not a dietitian either.

The minimum training that keeps the tissue

Protein without loading is an incomplete signal. Resistance training tells the organism which protein to keep. The advisory’s floor is strength training at least three times a week plus at least 150 minutes a week of moderate-intensity aerobic activity.^[2]

The reason to prefer that over cardio alone is not aesthetic. Villareal and colleagues randomized dieting adults over 65 to aerobic training, resistance training, both, or neither. Lean mass fell about 5 percent in the aerobic-only arm, about 2 percent with resistance training and about 3 percent with both, while the combined arm improved a physical performance battery by 21 percent against 14 percent for either alone.^[3] A deficit plus cardio is the arm that lost the most muscle and bought the least function.

Adding a drug does not change the shape of that finding. When Lundgren and colleagues randomized post-diet adults to exercise, liraglutide, both, or placebo, the combination cut body-fat percentage by 3.9 points against 1.7 for exercise alone and 1.9 for the drug alone, and only the combination improved glycated hemoglobin, insulin sensitivity and cardiorespiratory fitness.^[4] The drug and the barbell are not competing interventions. They are the same intervention, missing a half each.

In practice, under GLP-1:

• Full-body or upper/lower patterns, at least three sessions a week, over pure cardio heroics.
• Progress load or reps on basic patterns: squat or leg press, hinge, push, pull, carry.
• Accept that energy will feel different; do not accept permanent deload to nothing.
• Add steps and zone 2 for metabolic and cardiovascular benefit, not as a substitute for loading.

If someone is too ill or unstable to train, that is a medical conversation. If someone is simply uninterested, they are choosing a different body composition outcome. Say it plainly.

Function is the lab value

DEXA is nice. Chair stands, grip, a work set you can compare monthly: those are available. Note that the trial arm which preserved the most lean tissue was also the arm that scored best on a walk, a stair climb and a chair rise, not on a photograph.^[3] A patient who is lighter but cannot rise from the floor without furniture is not “optimized.” They are prepared for a worse old age with better bloodwork. Metabolic panels still matter; so do nutritional markers if intake has been chaotic.

Something still beats nothing

For a person with obesity, fatty liver, rising A1c and knee pain, twenty kilos off, even with some lean loss, can unlock movement, adherence and cardiovascular risk reduction that the outcome data takes seriously. In SELECT, 17,604 adults with established cardiovascular disease and a BMI of 27 or above but no diabetes were randomized to semaglutide 2.4 mg or placebo. Cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5 percent on semaglutide against 8.0 percent on placebo over a mean 39.8 months of follow-up, a hazard ratio of 0.80.^[5] Perfect body composition can become a weapon against starting. Something beats nothing.

Something with protein and lifting still beats something without, and the gap compounds for a decade. Longevity is the second derivative.

Losing the weight, keeping the muscle

Write the grams. Lift the weights. Check the function. Use the drug as a tool inside that frame, the same way a serious stack treats sleep and training as non-negotiable.^[6]

If the protocol has no protein number, it is not a longevity protocol. It is a weight story with better PR.

---

1. Neeland IJ, Linge J, Birkenfeld AL, Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies, Diabetes Obes Metab 2024;26(Suppl 4):16-27. doi:10.1111/dom.15728. Reported lean mass reductions range from 40-60% of total weight lost in some studies to roughly 15% or less in others. See also GLP-1 Won’t Train for You.
2. Mozaffarian D et al., Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, Obesity (Silver Spring) 2025;33(8):1475-1503. doi:10.1002/oby.24336. Source of the 1.2-1.6 g/kg/day target, the 2 g/kg/day ceiling, the 80-120 g/day absolute alternative, the three-strength-sessions-plus-150-minutes floor, and the STEP 1 body-composition figures (13.6 kg mean reduction, 8.3 kg fat, 5.3 kg lean).
3. Villareal DT et al., Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults, N Engl J Med 2017;376(20):1943-1955. doi:10.1056/NEJMoa1616338. Lean mass fell 2.7 kg (aerobic), 1.0 kg (resistance) and 1.7 kg (combined); Physical Performance Test scores rose 14%, 14% and 21%.
4. Lundgren JR et al., Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined, N Engl J Med 2021;384(18):1719-1730. doi:10.1056/NEJMoa2028198.
5. Lincoff AM et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), N Engl J Med 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. Primary endpoint 6.5% vs 8.0%; HR 0.80, 95% CI 0.72-0.90, P<0.001.
6. My longevity protocol; Longevity Doctors Agreed on Sleep.